Learn more on the refractive and non-refractive enhancements to achieve the best possible visual outcome after cataract surgery. Current Opinion in Ophthalmology
Uncategorized
Cell therapy for atrophic AMD well tolerated when delivered safely
MIAMI — Cell therapy with CNTO 2476, an adult stem cell treatment for atrophic age-related macular degeneration, is well tolerated when delivered safely into the subretinal space, a speaker told colleagues at Angiogenesis, Exudation, and Degeneration 2015.Of the 35 subjects with bilateral geographic atrophy enrolled in the study, 33 received the cells via microcatheter.
BRVO: Bevacizumab and Ranibizumab Both Effective
Treatment with anti-VEGF therapy results in rapid improvements in anatomy and function in patients with macular edema caused by branch retinal vein occlusion. Medscape Medical News
Uncategorized
Phase 2 study initiated for oral anti-VEGF, anti-PDGF inhibitor
MIAMI — An oral tyrosine kinase inhibitor under study for use in treating wet age-related macular degeneration has moved forward into a phase 2 trial, a speaker said.Reporting positive phase 1 study results for X-82 (Xcovery Vision), an inhibitor of both anti-VEGF and anti-PDGF activity, Jason S. Slakter, MD, said at Angiogenesis, Exudation, and Degeneration 2015, “[X-82] has low toxicity in oral administration. Phase 1 study has shown some anatomic benefit, and a phase 2 program is kicking off.”
Roche announces acquisition of Signature Diagnostics
Roche announced today the acquisition of Signature Diagnostics AG, a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, …
Uncategorized
VIDEO: Range of MIGS devices in development continues to expand
SAN FRANCISCO – At Glaucoma 360, Thomas W. Samuelson, MD, discusses the nine companies presenting different micro-incisional and micro-invasive glaucoma devices this year, exemplifying the growth in the burgeoning sector of glaucoma surgery.